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Abstract
Plasma interleukin (IL)-8 levels were monitored in 58 patients with metastatic breast cancer before and during
ﬁrst-line chemotherapy, and changes in the IL-8 levels were correlated with patient survival data. Monitoring
plasma IL-8 levels before and during chemotherapy identiﬁes patients with excellent prognosis whose IL-8
levels stay constantly below 16.6 pg/mL.
Background: Interleukin (IL)-8 is a proinﬂammatory cytokine, and high levels of IL-8 are associated with poor prog-
nosis in many malignancies. The objective of this study was to explore the clinical beneﬁt of monitoring plasma IL-8
levels during breast cancer chemotherapy. Patients and Methods: We conducted an exploratory analysis of several
circulating proteins, including IL-8, in the plasma. Plasma samples were obtained from 58 metastatic breast cancer
patients who took part in a prospective phase 2 ﬁrst-line bevacizumab chemotherapy trial. Samples were analyzed
before therapy, after 6 weeks and 6 months of treatment, and at the ﬁnal study visit. On the basis of a trajectory
analysis of the plasma IL-8 levels, the patients were divided into 3 trajectory groups. Results: Plasma IL-8, IL-6, IL-18,
matrix metalloproteinase (MMP)-2, MMP-9, YKL-40, resistin, and high-mobility group box 1 (HMGB1) concentrations
were measured, and the most pronounced predictor of patient survival was IL-8. On the basis of the trajectory analysis
of the IL-8 levels, the majority of patients (n ¼ 35, 60%) belonged to trajectory group 1, and these patients had
signiﬁcantly lower IL-8 levels before and during the entire chemotherapy treatment period than did the patients in the
other groups. Trajectory group 1 patients had signiﬁcantly better overall survival compared to patients in trajectory
group 2 (n ¼ 17; age-adjusted HR ¼ 2.45; 95% conﬁdence interval, 1.21-5.97; P ¼ .012) and 3 (n ¼ 6; age-adjusted
HR ¼ 8.65; 95% conﬁdence interval, 3.16-23.7; P < .001). Conclusion: Low IL-8 levels during chemotherapy treat-
ment might help identify patients with prolonged survival.
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Breast cancer is the most common cause of cancer-related death
in women.1 Currently, patients with human epidermal growth
factor 2 (HER2)-negative advanced breast cancer will survive for
approximately 2 to 3 years after diagnosis of advanced cancer.2-51Department of Oncology, Faculty of Medicine and Health Technology
2Research, Development and Innovation Center, Tampere University Hospital and
Health Sciences, Faculty of Social Sciences, Tampere University, Tampere, Finland
3Department of Oncology, Tampere University Hospital, Tampere, Finland
4The Immunopharmacology Research Group, Faculty of Medicine and Health
Technology, Tampere University and Tampere University Hospital, Tampere, Finland
5Department of Oncology and Radiotherapy and FICAN West Cancer Center, Turku
University Central Hospital, Turku, Finland
- Clinical Breast Cancer August 2019The disease of most patients will respond to chemotherapy and
endocrine therapy, but the cancer will eventually progress. More
investigational effort should be expended to ﬁnd patients with
disease that will not respond to current therapies and who are in
need of novel investigational treatment options. Furthermore, early6Department of Oncology and Radiotherapy, Medical Research Center Oulu, Oulu
University Hospital and University of Oulu, Oulu, Finland
Submitted: Dec 6, 2018; Revised: Feb 14, 2019; Accepted: Mar 16, 2019; Epub: Apr
4, 2019
Address for correspondence: Leena Tiainen, Department of Oncology, Tampere
University Hospital, Teiskontie 35, FI-33521 Tampere, Finland
Fax: þ358 331163019; e-mail contact: leena.tiainen@tuni.ﬁ
1526-8209/ª 2019 The Authors. Published by Elsevier Inc. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
https://doi.org/10.1016/j.clbc.2019.03.006
palliative care improves patient quality of life, symptom manage-
ment, and even treatment outcomes.6-8 In particular, patients with
chemoresistant cancer might beneﬁt from earlier palliative symptom
management if these patients could be better identiﬁed.
Interleukin (IL)-8 (alternatively known as CXCL8) is a proin-
ﬂammatory cytokine.9 Its complex effects on the tumor microen-
vironment may result in tumor proliferation, survival, and
chemoresistance in malignant disease.10-14 High IL-8 serum levels
and tumor expression are known to be associated with poor patient
prognosis in many malignant diseases, including breast can-
cer.13,15,16 Even in localized breast cancer, patients with high
circulating IL-8 levels have a poorer prognosis than patients with
low IL-8 levels.17,18
In addition to IL-8, many other cytokines and circulating regu-
latory factors are associated with breast cancer and are considered to
be potential biomarkers for cancer prognosis.19-34 Serum concen-
trations of IL-6 and IL-18 are elevated in breast cancer patients,19,20
and high circulating IL-6 levels are linked to shorter survival in
metastatic breast cancer patients than are low circulating IL-6
levels.21,22 Additionally, IL-6 and IL-18 are associated with
chemotherapy resistance.23,24 Matrix metalloproteinase (MMP)-2
and MMP-9 serum levels are associated with poor overall survival
(OS), even in patients with localized breast cancer.25 YKL-40 (also
known as chitinase-3elike protein 1) has been suggested to play a
role in cell proliferation, differentiation, inﬂammation, and tissue
remodeling, and has been associated with malignancies with poor
survival.35-37 In patients with either local or advanced breast cancer,
high serum YKL-40 levels predict a poor prognosis.26-28
Obesity is a known risk factor for breast cancer.38 Therefore,
adipocytokines, including resistin, may be related to breast cancer
development and prognosis. Serum resistin levels are known to be
elevated in breast cancer patients compared to healthy controls.29,30
Additionally, compared to low resistin expression, high resistin
expression in the primary breast cancer tumor tissue is associated
with poorer patient survival and more unfavorable clinicopathologic
features of the primary cancer.31 High-mobility group box 1
(HMGB1) is a ubiquitous nuclear protein that contributes to DNA
repair and the stabilization of nuclear homeostasis.32 HMGB1 is
expressed at higher levels in many tumor types compared to healthy
tissue,33 and its expression is associated with many diseases,
including cancer.34
We conducted an exploratory analysis of multiple plasma cyto-
kines and other circulating proteins. The aim of the study was to
identify prognostic markers for metastatic breast cancer. IL-8 levels,
a promising biomarker, were explored before and during chemo-
therapy treatment for their value in predicting patient prognosis.
We also measured plasma levels of IL-6, IL-18, MMP-9, MMP-2,
YKL-40, resistin, and HMGB1, and investigated their prognostic
signiﬁcance.
Patients and Methods
We conducted a prospective phase 2 trial for metastatic breast
cancer patients. The study patients had histologically veriﬁed
HER2-negative advanced breast cancer and had not received pre-
vious chemotherapy in a metastatic setting. A total of 65 patients
were enrolled onto the trial at 3 Finnish university oncology clinics
between 2009 and 2013 (NCT00979641). The study inclusioncriteria, trial design, and clinical results have been published pre-
viously.2 In brief, study patients were treated with a bevacizumab
and taxane (paclitaxel or docetaxel) combination as the ﬁrst-line
treatment for metastatic breast cancer. Patients without disease
progression continued bevacizumab treatment after the taxane
chemotherapy was discontinued. Patients with estrogen
receptorepositive breast cancer also received endocrine therapy with
bevacizumab maintenance therapy. For second-line therapy after
disease progression, the continuation of bevacizumab was optional
with chemotherapy. All patients provided written informed consent,
and the regional ethics committee of Tampere University Hospital
approved the study protocol (R08142M).
Plasma samples were gathered before the initiation of chemo-
therapy (baseline), after 6 weeks of treatment, after 6 months of
treatment, and at the ﬁnal study visit.
Measurement of Plasma Cytokines
Plasma IL-8, IL-6, IL-18, MMP-2, MMP-9, YKL-40, resistin,
and HMGB1 concentrations were measured by enzyme-linked
immunosorbent assays (ELISAs) using reagents from BD Bio-
sciences (Erembodegem, Belgium; IL-8), eBioscience (San Diego,
CA; IL-6 and IL-18), R&D Systems Europe (Abingdon, UK;
MMP-2, MMP-9, YKL-40, resistin), and IBL International
(Hamburg, Germany; HMGB1). ELISAs were carried out accord-
ing to a standard protocol. In brief, for MMP-2, MMP-9, YKL-40,
and resistin, a 96-well plate was coated with capture antibody and
incubated overnight at 4C. The wells were washed with phosphate-
buffered salinee0.05% Tween 20 and blocked with 1% bovine
serum albumin in phosphate-buffered saline, 250 mL per well, for 1
hour at room temperature (RT). The wells were washed, and the
standards, and samples diluted in reagent diluent (1% bovine serum
albumin in phosphate-buffered saline) were added to the wells and
incubated for 2 hours at RT. The wells were washed. Detection
antibodies diluted in reagent diluent (with normal goat serum for
MMP-9) were added and incubated for 1.5 h at RT. Streptavidin-
conjugated to horseradish peroxidase was added after the wash step
and incubated for 15 minutes at RT. The wells were washed, and
BioFX TMB substrate solution (SurModics, Eden Prairie, MN) was
added and incubated for 15 minutes in the dark at RT. After adding
50 mL of stop solution (1 N H2SO4), the absorbance of each well
was measured at 450 nm with a correction wavelength at 540 nm
within 20 minutes with a Victor3 Multilabel Counter (Perkin
Elmer, Turku, Finland), and the results were calculated from a
standard curve using the smoothed spline method with MultiCalc
software (Perkin Elmer). For IL-8, IL-6, IL-18, and HMGB1,
ELISAs were performed according to the manufacturer’s protocols
and then measured and calculated as stated above.
Patient Characteristics
Plasma samples were available from 58 patients (89%). Patient
characteristics are listed in Table 1. After taxane discontinuation,
patients without disease progression and with hormone
receptorepositive disease received endocrine therapy in combina-
tion with bevacizumab. Letrozole was the most common endocrine
therapy choice (n ¼ 19). The other endocrine therapies included
anastrozole (n ¼ 4), exemestane (n ¼ 4), tamoxifen (n ¼ 3), and
fulvestrant (n ¼ 3).Clinical Breast Cancer August 2019 - e523
Table 1 Baseline Characteristics and Efﬁcacy Results in
Plasma Biomarker Population and of Patients With
Baseline Samples Available Compared to Overall
Study Population
Characteristic
Plasma Biomarker
Population
(N [ 58)
Overall Study
Population
(N [ 65)
Age (y), median (range) 58 (32-75) 57 (32-75)
Menopausal Status
Premenopausal 9 (15.5) 10 (15.4)
Postmenopausal 49 (84.5) 55 (84.6)
History of early stage
disease
52 (89.7) 57 (87.7)
Disease-Free Interval, mo
24 10 (19.2) 11 (16.9)
>24 42 (80.8) 46 (70.8)
Hormone Receptor Status
ERþ and/or PRþ 47 (81.0) 53 (81.5)
ER and PR 11 (19.0) 12 (18.5)
No. of Metastatic Lesions
3 11 (19.0) 14 (21.5)
>3 47 (81.0) 51 (78.5)
Extent of Disease
<3 sites 36 (62.1) 39 (60.0)
3 sites 22 (37.9) 26 (40.0)
Site of Metastatic Disease
Visceral disease 46 (79.3) 53 (81.5)
Nonvisceral disease 12 (20.7) 12 (18.5)
Overall survival, median
(95% CI)
37.5 (25.4-49.6) 35.1 (22.2-50.3)
Progression-free survival,
median (95% CI)
11.3 (8.3-14.4) 11.3 (9.7-16.0)
Best Response to
Treatment
Complete response/partial
response
38 (71.7) 40 (61.5)
Stable disease 13 (24.5) 15 (23.1)
Progressive disease 2 (3.8) 3 (4.6)
Data are presented as n (%) unless otherwise indicated.
Abbreviations: CI ¼ conﬁdence interval; ER ¼ estrogen receptor; PR ¼ progesterone receptor.
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progression was the reason for study discontinuation for most pa-
tients (n ¼ 36, 55%). Final plasma samples were available from 50
patients, of whom 24 had disease progression as the reason for
treatment discontinuation (48%). The remaining 26 patients dis-
continued the study treatment as a result of treatment side effects.
Plasma samples at week 6 and month 6 were available only from
patients who were following the study treatment plan at that time
point.
Statistical Analysis
The statistical plan for the analysis was exploratory. IL-8, IL-6,
IL-18, MMP-9, MMP-2, YKL-40, resistin, and HMGB1 levels- Clinical Breast Cancer August 2019were dichotomized as low or high for each patient using the median
value for each molecule as the cutoff value. Additionally, IL-8, IL-6,
IL-18, MMP-9, MMP-2, YKL-40, resistin, and HMGB1 levels
were divided into 4 groups using the baseline quartile ranges as the
cutoff values.
IL-8 values were clustered by the trajectory analysis originally
presented by Nagin.39 Trajectory groups are clusters of individuals
following similar trajectories to an outcome over time.40 The tra-
jectories were created according to all measurements of IL-8 levels in
each patient as a continuous outcome measure. These trajectories
are presented in Figure 1. The analyses undertaken were latent class
mixture models of quadratic trajectories including a random inter-
cept and concomitant variables. Models were ﬁtted by the FlexMix
package41 of the statistical program R 3.3.0.42 Relative goodness of
ﬁt was assessed using the Bayesian information criteria.
Because of the nonparametric distribution of the IL-8 levels,
medians with the conﬁdence interval (CI) of the median are re-
ported. The Mann-Whitney U test was used to compare the median
IL-8 levels of different baseline characteristics and trajectory groups.
Hazard ratios (HR) with 95% CIs were calculated by Cox pro-
portional hazard regression analysis. Multivariable analyses were
adjusted for age (continuous), menopause status (premenopausal/
postmenopausal), hormone receptor status (negative/positive),
presence of visceral metastasis (yes/no), number of metastatic lesions
(cutoff of 3 metastatic lesions), and extent of disease (cutoff of 3
metastatic sites). Median OS, median progression-free survival
(PFS), and their CIs were calculated by the Kaplan-Meier method.
The Wilcoxon signed-rank test was used to compare the baseline,
week 6, month 6, and ﬁnal plasma IL-8 levels between the different
trajectory groups. P < .05 was considered statistically signiﬁcant.
Statistical analyses were performed by SPSS 23 software (IBM,
Armonk, NY).
Results
IL-8 Levels and Patient Baseline Characteristics
There were no statistically signiﬁcant differences in the baseline
IL-8 levels between groups with different baseline characteristics,
including menopause status (P ¼ .104), hormone receptor status
(P ¼ .152), number of metastatic lesions (P ¼ .539), and presence
of visceral disease (P ¼ .941). Borderline signiﬁcantly lower baseline
IL-8 levels were observed in patients with <3 metastatic sites
compared to the patients with 3 metastatic sites (<3 metastatic
sites median baseline IL-8: 8.9 pg/mL; 95% CI, 7.8-9.9 pg/mL
vs. 3 metastatic sites median IL-8: 12.5 pg/mL; 95% CI, 8.0-25.4
pg/mL; P ¼ .057).
Prognostic Signiﬁcance of Baseline IL-8 Levels
The patients were divided into two groups (low and high baseline
plasma IL-8 level) using a median value of 9.4 pg/mL as the cutoff
point. The PFS and OS of these IL-8 groups are listed in Table 2.
The high baseline IL-8 group had a signiﬁcantly shorter OS
(P ¼ .023).
Trajectory Analysis of IL-8 Levels
The distributions of the 3 trajectory groups are presented in
Figure 1 and Table 3. Trajectory group 1 patients had constantly
low IL-8 concentrations; the range of IL-8 levels in trajectory group
Figure 1 Interleukin 8 Trajectory Groups. Shown Are
Trajectory Groups 1 (n [ 35), 2 (n [ 17), and 3
(n [ 6)
Trajectory groups
nikuelretnI
-
)l
m/gp( 8
Baseline
Week 6
Month 6
Final
Leena Tiainen et al1 was 2.6 to 16.6 pg/mL during the entire treatment period. Tra-
jectory groups 2 and 3 had signiﬁcantly higher IL-8 levels at base-
line, at week 6, at month 6, and at the ﬁnal study visit compared to
trajectory group 1 (Table 3). The ﬁnal IL-8 levels of trajectory
group 3 patients were signiﬁcantly higher than their month 6 IL-8
plasma levels (P ¼ .043). In trajectory group 3, there were no
signiﬁcant changes in the IL-8 levels between the baseline and week
6 and between week 6 and month 6. The changes in the IL-8 levels
in trajectory groups 1 and 2 over time were not statistically
signiﬁcant.
The patients belonging to trajectory group 3 with very high IL-8
levels had signiﬁcantly shorter PFS than the patients belonging to
the other groups (Table 4, Figure 2A). No signiﬁcant differences in
PFS were detected between the patients in trajectory groups 1 andTable 2 Cox Regression Analysis for PFS and OS Grouped by Low
Baseline IL-8 pg/mL No. Patients No. Events
A
HR
PFS
Low 9.4 27 15 1
High >9.4 26 16 1.44
OS
Low 9.4 27 16 1
High >9.4 26 23 2.14
Abbreviations: CI ¼ conﬁdence interval; HR ¼ hazard ratio; IL ¼ interleukin; OS ¼ overall survival
aHR adjusted for age.
bHR adjusted for age, menopause status, hormone receptor status, presence of visceral metastasis
cStatistically signiﬁcant.2. In addition, the patients in trajectory groups 2 and 3 had
signiﬁcantly shorter OS than the patients in trajectory group 1 using
both an age-adjusted HR and a multivariable Cox model adjusted
for age, menopause status, hormone receptor status, presence of
visceral metastases, number of metastatic lesions, and extent of the
disease (Table 4, Figure 2B).
To further examine the clinical utility of IL-8 levels, a cutoff
value of 16.6 pg/mL was found to be useful for ﬁnding patients with
a signiﬁcantly more favorable long-term prognosis. All the IL-8
levels in trajectory group 1 remained below 16.6 pg/mL before
and during the entire chemotherapy treatment period. A cutoff
value of 16.6 pg/mL could identify all of the 35 patients who were
categorized into trajectory group 1. In contrast, only one trajectory
group 2 patient (1/17, 5.9%) had IL-8 levels constantly below 16.6
pg/mL, and all of the patients in trajectory group 3 had IL-8 levels
higher than 16.6 pg/mL before or during chemotherapy treatment.
For PFS, the age-adjusted HR was borderline signiﬁcant for the
patients with IL-8 levels higher than 16.6 pg/mL before or during
chemotherapy treatment (age-adjusted HR 2.00; 95% CI, 0.97-
4.14; P ¼ .060), while the multivariable HR was not statistically
signiﬁcant (multivariable HR ¼ 1.91; 95% CI, 0.89-4.09; P ¼
.094; Figure 3A). However, the HR for OS was strongly signiﬁcant
for both the age-adjusted and multivariable Cox models for the
patients with IL-8 levels higher than 16.6 pg/mL before or during
chemotherapy treatment (age-adjusted HR 3.02; 95% CI, 1.60-
5.71; P ¼ .001, multivariable HR ¼ 3.90; 95% CI, 1.88-8.12; P <
.001; Figure 3B).
Highest Baseline IL-8 Quartile Level and Prognosis
A very high baseline plasma IL-8 level was also a strong sign of
poor prognosis without knowledge of IL-8 levels during treatment.
The highest (>18.8 pg/mL) baseline IL-8 level quartile patients had
the poorest prognosis in terms of median PFS and OS, at 9.6
months (95% CI, 5.47-13.7 months) and 19.7 months (95% CI,
8.60-30.9 months), respectively (Supplemental Table 1 in the on-
line version). The multivariable HR for PFS was 6.52 (95% CI,
1.58-26.9; P ¼ .010) for the highest plasma IL-8 quartile, and the
multivariable HR for OS was 8.38 (95% CI, 2.60-27.0; P < .001).
All of the patients in the highest quartile belonged to trajectory
groups 2 (n ¼ 9) and 3 (n ¼ 4). Altogether, a high baseline IL-8
level > 18.8 pg/mL (the highest quartile) could identify 62%or High Baseline IL-8 Levels Using Median as Cutoff Value
djusted HR 1a Adjusted HR 2b
95% CI P HR 95% CI P
1
0.70-2.93 .316 1.32 0.58-3.00 .493
1
1.10-4.12 .023c 1.65 0.82-3.34 .159
; PFS ¼ progression-free survival.
, number of metastatic lesions, and extent of disease.
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Table 3 Median IL-8 Levels in 3 Trajectory Groups
Trajectory
Group No. Patients
Baseline IL-8 (pg/mL) Week 6 IL-8 (pg/mL) Month 6 IL-8 (pg/mL) Final IL-8 (pg/mL)
Median 95% CI Median 95% CI Median 95% CI Median 95% CI
1 35 8.05 7.40-9.40 7.30 5.90-9.00 7.60 6.50-8.90 7.90 6.30-9.90
2 17 21.7 12.4-27.5 13.4 11.3-18.0 11.6 8.40-16.1 15.1 7.30-20.2
3 6 38.9 9.30-175 16.2 11.9-50.2 39.4 9.50-93.4 78.9 56.4-113
1 vs. 2 P <.001a <.001a .006a .001a
1 vs. 3 P .002a .002a <.001a <.001a
2 vs. 3 P .199 .332 .009a .001a
Abbreviations: CI ¼ conﬁdence interval of median; IL ¼ interleukin.
aStatistically signiﬁcant.
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and 3 with the baseline plasma samples available.
IL-6, IL-18, MMP-9, MMP-2, YKL-40, Resistin, and
HMGB1 Baseline Levels as Prognostic Markers for
Survival
A Cox regression analysis was also performed for all other
measured markers: IL-6, IL-18, MMP-9, MMP-2, YKL-40, resis-
tin, and HMGB1. Using the median and quartile levels as cutoff
values, there were no statistically signiﬁcant differences in PFS using
all individual markers (Supplemental Tables 2 and 3 in the online
version). Using the median as a cutoff value, a high baseline MMP-
9 level was borderline signiﬁcant for longer OS (multivariable HR¼
0.52; 95% CI, 0.26-1.03; P ¼ .063). Using the baseline quartile
levels as cutoff values, the baseline quartile level of 50% to 75% for
MMP-9 was prognostic for OS (multivariable HR ¼ 0.37; 95% CI,
0.13-1.01; P ¼ .054), as was the highest baseline quartile MMP-9
level (multivariable HR for OS 0.22; 95% CI, 0.07-0.68; P ¼
.009). The highest baseline quartile level of YKL-40 was a sign of
poor prognosis in an age-adjusted Cox regression (HR 3.08; 95%
CI, 1.10-8.61; P ¼ .031). However, in multivariable analysis, the
highest baseline level of YKL-40 lost its prognostic signiﬁcance
(multivariable HR ¼ 2.13; 95% CI, 0.65-6.97; P ¼ .211). For
IL-6, IL-18, MMP-2, resistin, and HMGB1, the median andTable 4 PFS and OS of Patients of 3 Trajectory Groups
Trajectory
Group No. Patients No. Events
HR 1
HR 95% C
PFS
1 35 19 1
2 17 9 1.27 0.52-3.
3 6 6 4.56 1.65-12
OS
1 35 22 1
2 17 15 2.45 1.21-5.
3 6 6 8.65 3.16-23
Abbreviations: CI ¼ conﬁdence interval; HR ¼ hazard ratio; IL ¼ interleukin; OS ¼ overall survival
aHR adjusted for age.
bHR adjusted for age, menopause status, hormone receptor status, presence of visceral metastasis
cStatistically signiﬁcant.
- Clinical Breast Cancer August 2019quartile cutoff level groups revealed no signiﬁcant OS differences
(Supplemental Tables 4 and 5 in the online version).
Discussion
IL-8 level monitoring during chemotherapy for metastatic breast
cancer is a promising approach for identifying patients with good
prognosis. High baseline plasma IL-8 levels are known to be a poor
prognosticmarker in breast cancer.15However, to our knowledge, our
study is novel in its monitoring of plasma IL-8 levels in metastatic
breast cancer patients during chemotherapy. We identiﬁed a large
group of patients belonging to trajectory group 1 (35/58, 60.3%)who
had a substantially better prognosis than the rest of the patients. The
median OS (50 months) for trajectory group 1 patients was excep-
tionally good (95%CI, 43.5-56.3months) in patients withmetastatic
HER2-negative breast cancer. In contrast, the median OS for tra-
jectory group 2 patients (median OS 24 months; 95% CI, 15.5-32.0
months) was less than half of the OS in the group 1 patients. Inter-
estingly, the remaining 6 patients belonging to trajectory group 3 had
exceptionally high IL-8 levels during the entire chemotherapy period,
and these patients had a short median OS of 8 months. High IL-8
levels are known to be a sign of chemoresistance.12,43 The poor sur-
vival of our trajectory group 3 patients is a conﬁrmatory ﬁnding for the
previously reported chemoresistant nature of metastatic cancer with
high IL-8 levels.a HR 2b
I P HR 95% CI P
1
08 .589 0.94 0.35-2.54 .917
.6 .003c 4.01 1.24-12.9 .020c
1
97 .012c 3.29 1.45-7.45 .004c
.7 <.001c 7.82 2.27-26.9 .001c
; PFS ¼ progression-free survival.
, number of metastatic lesions, and extent of disease.
Figure 2 PFS and OS by Multivariable Cox Regression. (A) PFS and (B) OS of 3 Trajectory Groups Using Multivariable Cox Regression
Adjusted for Age, Menopause Status, Hormone Receptor Status, Presence of Visceral Metastasis, Number of Metastatic
Lesions, and Extent of Disease. Median Survivals and Their Conﬁdence Intervals Were Calculated by Kaplan-Meier Method.
*Log-rank P Value Between Trajectory Groups 1 and 2. **Log-rank P Value Between Trajectory Groups 1 and 3
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Abbreviations: OS ¼ overall survival; PFS ¼ progression-free survival.
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treatment. In our study, the IL-8 levels in the highest baseline
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Analysis Using All Plasma IL-8 Levels Before and During C
Levels at Baseline, Week 6, Month 6, and at Study Discon
Several Measurements of Plasma IL-8 Levels Are Above 16.
Cox Regression Adjusted for Age, Menopause Status, Horm
Metastatic Lesions, and Extent of Disease. Median Surviva
Meier Method
Pr
og
re
ss
io
n-
fr
ee
 s
ur
vi
va
l
Number at risk
≤ 16.6 pg/ml 36 28 14 10 3 1
> 16.6 pg/ml 22 16 5 2 2 2
Time (months)
Median months 
(95% CI)
IL-8 ≤ 16.6 pg/ml 13.9 (7.74-20.1)
IL-8 > 16.6 pg/ml 10.2 (8.43-11.9)
Log rank p value 0.094
A
Abbreviations: IL ¼ interleukin; OS ¼ overall survival; PFS ¼ progression-free survival.HR ¼ 6.52; 95% CI, 1.58-26.9; P ¼ .010) and OS (multivariable
HR ¼ 8.38; 95% CI, 2.60-27.0; P < .001) of these patients were
signiﬁcantly shorter than those of the patients in the lowest IL-8
quartile group. This result was similar to a previous report that
showed that patients with baseline plasma IL-8 levels higher than) OS in Patient Population Dichotomized Based on Trajectory
hemotherapy Treatment. Red Line Indicates That Plasma IL-8
tinuation Are Below 16.6 pg/mL. Blue Line Indicates That One or
6 pg/mL Before or During Chemotherapy Treatment. Multivariable
one Receptor Status, Presence of Visceral Metastasis, Number of
ls and Their Conﬁdence Intervals Were Calculated by Kaplan-
O
ve
ra
ll 
su
rv
iv
al
Number at risk
≤ 16.6 pg/ml 36 36 33 30 29 27 25 21 15 9 9 8 7
> 16.6 pg/ml 22 21 15 13 8 6 5 5 3 2 2 2 1
Time (months)
Median months 
(95% CI)
IL-8 ≤ 16.6 pg/ml 47.5 (41.2-53.9)
IL-8 > 16.6 pg/ml 20.5 (15.6-25.4)
Log rank p value <0.001
B
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e528the median value of 17.2 pg/mL had shorter survival than patients
with lower IL-8 levels (P ¼ .0045).15
Several studies have been conducted to ﬁnd a clinically useful
biomarker to select patients who might beneﬁt from the addition of
the vascular endothelial growth factor A (VEGF-A) antibody bev-
acizumab to standard chemotherapy for the treatment of metastatic
breast cancer.44-48 In our study, the patients were treated with
bevacizumab combined with either paclitaxel or docetaxel chemo-
therapy as ﬁrst-line treatment for metastatic breast cancer. It has
been shown that IL-8 can promote angiogenesis and may activate
vascular endothelial growth factor receptor 2 (VEGFR2).49 VEGF-
A is a ligand for VEGFR2. In our study, very high baseline IL-8
levels were a sign of poor prognosis. Accordingly, in our study,
the patients with the highest plasma IL-8 levels at baseline had the
shortest treatment beneﬁt. The high baseline plasma levels of
proangiogenic IL-8 might be one reason for the lack of beneﬁt from
bevacizumab-based therapy. However, because our study did not
have a placebo control arm as a comparator, this hypothesis should
be tested prospectively in future studies.
The other markers analyzed in our study failed to demonstrate
any clear prognostic signiﬁcance. Zhang and Adachi21 reported that
patients with circulating IL-6 levels higher than the median con-
centration of 4 pg/mL in their study exhibited poor survival.
However, the highest quartile plasma IL-6 cutoff value for our study
patients was 3.8 pg/mL, suggesting that most of our study patients
had low plasma IL-6 concentrations. This is in accordance with the
ﬁnding that plasma IL-6 levels were not prognostic in our hands. In
addition, the limited patient population in our study might partly
explain why the other tested circulating markers had no prognostic
value.
The plasma analyses in our study were exploratory and were
performed retrospectively. In the future, it would be useful to
monitor plasma IL-8 levels prospectively in clinical trials involving
metastatic breast cancer patients. IL-8 levels are known to correlate
with the tumor burden in many malignant diseases.50 Rising IL-8
levels during treatment could be a sign of chemoresistance, and it
therefore might be beneﬁcial to refer patients with rising IL-8 levels
to new treatment modalities. It might be worthwhile to study
whether patients with high plasma concentrations of the proin-
ﬂammatory cytokine IL-8 would beneﬁt from novel immunother-
apies. In an unselected metastatic breast cancer population, the
response rates to immunotherapies have been low.51 However, in a
report of novel immunotherapies, a clear association was seen be-
tween the treatment response and IL-8 levels in melanoma and
nonesmall-cell lung cancer patients.52 Nevertheless, the correlation
between high IL-8 levels and the response rates to immunotherapies
in metastatic breast cancer remains unexplored.
Conclusion
Low plasma IL-8 levels during chemotherapy in metastatic breast
cancer patients are a clear sign for excellent long-term prognosis. We
found that patients with constantly low plasma IL-8 levels had a better
prognosis than the patients with plasma IL-8 levels higher than 16.6
pg/mL. Plasma IL-8 levels might therefore be useful for the selection
of patients with excellent prognosis and those who might be suitable
for less intensive radiologic imaging and follow-up visits.- Clinical Breast Cancer August 2019Clinical Practice Points
 High circulating IL-8 levels are associated with poor prognosis in
patients with advanced breast cancer and are related to
chemoresistance.
 Metastatic breast cancer patients with constantly low plasma IL-8
levels during ﬁrst-line chemotherapy have an excellent long-term
prognosis.
 Very high baseline plasma IL-8 levels are associated with
signiﬁcantly shorter PFS and OS.
 Monitoring circulating IL-8 levels during ﬁrst-line chemotherapy
might be beneﬁcial to distinguish good-prognosis patients who
might be suited to less intensive treatment and follow-up
schedules.
 Patients with very high plasma IL-8 levels either at the beginning
of chemotherapy treatment or during therapy for metastatic
breast cancer should be followed more intensively because of the
chemoresistant nature of their disease.
 In the future, whether patients with high plasma IL-8 levels and
therefore poor prognosis might beneﬁt from novel treatment
modalities, ie, immunologic therapy, should be prospectively
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Supplemental Table 1 PFS and OS for Study Patients Grouped by Baseline IL-8 Quartile
Baseline IL-8 pg/mL No. Patients No. Events
HR 1a HR 2b
HR 95% CI P HR 95% CI P
PFS
<Q25 <7.7 13 5 1 1
Q25-Q50 7.7-9.4 14 10 2.12 0.70-6.39 .180 2.15 0.53-8.65 .279
Q50-Q75 9.4-18.8 13 7 1.34 0.42-4.27 .618 0.99 0.20-4.76 .995
>Q75 >18.8 13 9 5.22 1.62-16.8 .006c 6.52 1.58-26.9 .010c
OS
<Q25 <7.7 13 6 1 1
Q25-Q50 7.7-9.4 14 10 2.70 0.95-7.69 .062 3.46 1.08-11.0 .035c
Q50-Q75 9.4-18.8 13 10 2.29 0.81-6.46 .115 1.64 0.51-5.28 .406
>Q75 >18.8 13 13 7.44 2.62-21.1 <.001c 8.38 2.60-27.0 <.001c
Abbreviations: CI ¼ conﬁdence interval; HR ¼ hazard ratio; IL ¼ interleukin; OS ¼ overall survival; PFS ¼ progression-free survival; Q ¼ quartile.
aHR adjusted for age.
bHR adjusted for age, menopause status, hormone receptor status, presence of visceral metastasis, number of metastatic lesions, and extent of disease.
cStatistically signiﬁcant.
Supplemental Table 2 Cox Regression Analysis for PFS Grouped by Low or High Baseline IL-6, IL-18, MMP-9, MMP-2, YKL-40,
Resistin, and HMGB1 Levels Using Median as Cutoff Value
Baseline Value No. Patients No. Events
HR 1a HR 2b
HR 95% CI P HR 95% CI P
IL-6 pg/mL
Low 1.8 27 15 1 1
High >1.8 26 16 0.84 0.40-1.73 .637 0.44 0.18-1.07 .071
IL-18 pg/mL
Low 99.2 27 17 1 1
High >99.2 26 14 0.60 0.29-1.25 .176 0.71 0.31-1.60 .411
MMP-9 ng/mL
Low 76.4 27 18 1 1
High >76.4 26 13 0.72 0.35-1.47 .370 0.56 0.25-1.29 .177
MMP-2 ng/mL
Low 244.5 27 15 1 1
High >244.5 26 16 0.91 0.42-1.95 .810 0.80 0.37-1.74 .585
YKL-40 ng/mL
Low 60.3 27 16 1 1
High >60.3 26 15 1.26 0.60-2.65 .536 0.951 0.40-2.22 .909
Resistin ng/mL
Low 13.4 27 15 1 1
High >13.4 26 16 1.44 0.69-2.99 .325 1.13 0.53-2.39 .749
HMGB1 ng/mL
Low 7.1 27 15 1 1
High >7.1 26 16 1.28 0.60-2.71 .512 1.27 0.59-2.71 .535
Abbreviations: CI ¼ conﬁdence interval; HMGB1 ¼ high-mobility group box 1; HR ¼ hazard ratio; IL ¼ interleukin; MMP ¼ matrix metalloproteinase; PFS ¼ progression-free survival.
aHR adjusted for age.
bHR adjusted for age, menopause status, hormone receptor status, presence of visceral metastasis, number of metastatic lesions, and extent of disease.
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Supplemental Table 3 PFS Analysis by Cox Regression for Study Patients Using Baseline IL-6, IL-18, MMP-9, MMP-2, YKL-40,
Resistin, and HMGB1 Quartile Levels as Cutoff Values
Baseline Value No. Patients
HR 1a HR 2b
HR 95% CI P HR 95% CI P
IL-6 pg/mL
<Q25 <0.7 15 1 1
Q25-Q50 0.7-1.8 12 0.85 0.30-2.40 .767 1.38 0.33-5.65 .652
Q50-Q75 1.8-3.8 14 0.57 0.21-1.57 .286 0.31 0.09-1.05 .060
>Q75 >3.8 12 1.23 0.43-3.55 .692 1.02 0.27-3.80 .973
IL-18 pg/mL
<Q25 <53.5 13 1 1
Q25-Q50 53.5-99.2 14 1.23 0.45-3.36 .676 1.11 0.40-3.13 .831
Q50-Q75 99.2-264.3 14 0.65 0.24-1.75 .401 0.70 0.24-2.01 .516
>Q75 >264.3 12 0.65 0.23-1.87 .432 0.81 0.24-2.69 .733
MMP-9 ng/mL
<Q25 <49.6 13 1 1
Q25-Q50 49.6-76.4 14 1.02 0.40-2.60 .963 0.84 0.28-2.47 .756
Q50-Q75 76.4-129.6 13 0.82 0.31-2.18 .700 0.68 0.24-1.92 .474
>Q75 >129.6 13 0.61 0.20-1.89 .396 0.34 0.09-1.30 .118
MMP-2 ng/mL
<Q25 <218.8 13 1 1
Q25-Q50 218.8-244.5 14 1.35 0.46-3.90 .579 1.43 0.44-4.70 .548
Q50-Q75 244.5-284.0 13 1.05 0.34-3.18 .927 0.96 0.27-3.36 .959
>Q75 >284.0 13 1.15 0.35-3.75 .807 1.05 0.31-3.46 .935
YKL-40 ng/mL
<Q25 <38.3 13 1 1
Q25-Q50 38.3-60.3 14 0.99 0.35-2.78 .995 1.68 0.54-5.28 .368
Q50-Q75 60.3-113.3 13 1.30 0.42-3.98 .640 1.24 0.42-3.70 .688
>Q75 >113.3 13 1.23 0.43-3.49 .698 1.03 0.27-3.89 .962
Resistin ng/mL
<Q25 <11.4 13 1 1
Q25-Q50 11.4-13.4 14 1.04 0.36-3.00 .931 1.43 0.40-5.06 .572
Q50-Q75 13.4-15.6 13 1.69 0.60-4.73 .315 2.06 0.61-6.99 .242
>Q75 >15.6 13 1.30 0.46-3.67 .609 1.01 0.33-3.06 .982
HMGB1 ng/mL
<Q25 <5.1 13 1 1
Q25-Q50 5.1-7.1 14 1.27 0.45-3.61 .643 0.74 0.24-2.30 .610
Q50-Q75 7.1-9.7 13 1.87 0.60-5.83 .281 2.29 0.62-8.45 .213
>Q75 >9.7 13 1.24 0.42-3.68 .688 0.76 0.24-2.35 .640
Abbreviations: CI ¼ conﬁdence interval; HMGB1 ¼ high-mobility group box 1; HR ¼ hazard ratio; IL ¼ interleukin; MMP ¼ matrix metalloproteinase; PFS ¼ progression-free survival; Q ¼ quartile.
aHR adjusted for age.
bHR adjusted for age, menopause status, hormone receptor status, presence of visceral metastasis, number of metastatic lesions, and extent of disease.
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Supplemental Table 4 Cox Regression Analysis for OS Grouped by Low or High Baseline IL-6, IL-18, MMP-9, MMP-2, YKL-40,
Resistin, and HMGB1 Levels Using Median as Cutoff Value
Baseline Value No. Patients No. Events
HR 1a HR 2b
HR 95% CI P HR 95% CI P
IL-6 pg/mL
Low 1.8 27 19 1 1
High >1.8 26 20 1.10 0.57-2.12 .771 1.12 0.52-2.39 .771
IL-18 pg/mL
Low 99.2 27 18 1 1
High >99.2 26 21 1.38 0.72-2.63 .319 1.21 0.60-2.43 .588
MMP-9 ng/mL
Low 76.4 27 21 1 1
High >76.4 26 18 0.73 0.38-1.37 .330 0.52 0.26-1.03 .063
MMP-2 ng/mL
Low 244.5 27 20 1 1
High >244.5 26 19 0.96 0.47-1.93 .910 1.42 0.66-3.05 .362
YKL-40 ng/mL
Low 60.3 27 18 1 1
High >60.3 26 21 1.87 0.94-3.73 .071 1.41 0.66-2.99 .370
Resistin ng/mL
Low 13.4 27 19 1 1
High >13.4 26 20 1.13 0.60-2.12 .701 1.09 0.56-2.13 .784
HMGB1 ng/mL
Low 7.1 27 20 1 1
High >7.1 26 19 0.93 0.47-1.86 .850 1.19 0.57-2.48 .626
Abbreviations: CI ¼ conﬁdence interval; HMGB1 ¼ high-mobility group box 1; HR ¼ hazard ratio; IL ¼ interleukin; MMP ¼ matrix metalloproteinase; PFS ¼ progression-free survival.
aHR adjusted for age.
bHR adjusted for age, menopause status, hormone receptor status, presence of visceral metastasis, number of metastatic lesions, and extent of disease.
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Supplemental Table 5 OS Analysis by Cox Regression for Study Patients Using Baseline IL-6, IL-18, MMP-9, MMP-2, YKL-40,
Resistin, and HMGB1 Quartile Levels as Cutoff Values
Baseline Value No. Patients
HR 1a HR 2b
HR 95% CI P HR 95% CI P
IL-6 pg/mL
<Q25 <0.7 15 1 1
Q25-Q50 0.7-1.8 12 2.66 1.04-6.77 .039c 1.64 0.48-5.60 .426
Q50-Q75 1.8-3.8 14 1.51 0.59-3.88 .386 0.92 0.31-2.65 .878
>Q75 >3.8 12 2.29 0.82-6.39 .111 2.23 0.76-6.54 .142
IL-18 pg/mL
<Q25 <53.5 13 1 1
Q25-Q50 53.5-99.2 14 0.67 0.26-1.73 .415 0.52 0.19-1.43 .205
Q50-Q75 99.2-264.3 14 0.80 0.31-2.00 .635 0.65 0.25-1.66 .369
>Q75 >264.3 12 1.62 0.66-3.96 .290 1.20 0.42-3.39 .729
MMP-9 ng/mL
<Q25 <49.6 13 1 1
Q25-Q50 49.6-76.4 14 0.50 0.20-1.21 .128 0.39 0.14-1.06 .067
Q50-Q75 76.4-129.6 13 0.50 0.20-1.23 .133 0.37 0.13-1.01 .054c
>Q75 >129.6 13 0.48 0.19-1.22 .128 0.22 0.07-0.68 .009c
MMP-2 ng/mL
<Q25 <218.8 13 1 1
Q25-Q50 218.8-244.5 14 1.93 0.75-4.99 .170 1.81 0.59-5.52 .295
Q50-Q75 244.5-284.0 13 1.21 0.41-3.56 .728 1.77 0.52-5.97 .356
>Q75 >284.0 13 1.73 0.61-4.91 .300 2.16 0.74-6.29 .158
YKL-40 ng/mL
<Q25 <38.3 13 1 1
Q25-Q50 38.3-60.3 14 1.56 0.56-4.32 .386 2.00 0.70-5.74 .195
Q50-Q75 60.3-113.3 13 1.97 0.63-6.06 .238 2.10 0.68-6.41 .191
>Q75 >113.3 13 3.08 1.10-8.61 .031c 2.13 0.65-6.97 .211
Resistin ng/mL
<Q25 <11.4 13 1 1
Q25-Q50 11.4-13.4 14 1.10 4.31-2.83 .835 0.97 0.30-3.08 .966
Q50-Q75 13.4-15.6 13 1.22 0.47-3.13 .673 1.26 0.46-3.45 .645
>Q75 >15.6 13 1.17 0.45-3.03 .744 0.95 0.35-2.55 .919
HMGB1 ng/mL
<Q25 <5.1 13 1 1
Q25-Q50 5.1-7.1 14 1.81 0.73-4.44 .195 1.65 0.65-4.21 .288
Q50-Q75 7.1-9.7 13 1.22 0.46-3.24 .679 1.95 0.67-5.63 .217
>Q75 >9.7 13 1.35 0.49-3.68 .550 1.34 0.48-3.72 .568
Abbreviations: CI ¼ conﬁdence interval; HMGB1 ¼ high-mobility group box 1; HR ¼ hazard ratio; IL ¼ interleukin; MMP ¼ matrix metalloproteinase; PFS ¼ progression-free survival; Q ¼ quartile.
aHR adjusted for age.
bHR adjusted for age, menopause status, hormone receptor status, presence of visceral metastasis, number of metastatic lesions, and extent of disease.
cStatistically signiﬁcant.
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